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ABSTRACT 
 
 
 
Amniotic Fluid Stem (AFS) cells are multipotent stem cells achievable through the positive 
selection and ex-vivo expansion of CD117 (c-Kit)-expressing cells derived from amniotic 
fluid. Given the broad differentiation potential toward adipogenic, osteogenic, myogenic, 
endothelial, neuronal and hepatic lineages, AFS cells have raised great interest as new 
therapeutic tool. However, their immunogenicity and immunomodulatory properties need 
to be assessed before clinical use. To this aim, we analyzed the immunological effects 
resulting from the interaction between AFS cells of different gestational age and a number 
of immune effector cells (IECs), i.e. T, B and NK cells.  
Resting 1st trimester-AFS cells showed lower expression of HLA class-I molecules and 
NK-activating ligands than 2nd and 3rd trimester-AFS cells. This feature was associated to 
lower sensitivity of 1st trimester-AFS cells to NK cell-mediated lysis. Nevertheless, 
inflammatory priming of AFS cells by IFN-γ and TNF-α enhanced the resistance of all AFS 
cell types to NK cell cytotoxicity.  
AFS cells modulated lymphocyte proliferation in a different manner according to 
gestational age: 1st trimester-AFS cells significantly inhibited T and NK cell proliferation, 
while 2nd and 3rd trimester-AFS cells were less efficient. In addition, only inflammatory-
primed 2nd trimester-AFS cells could suppress B cell proliferation, which was on the 
contrary unaffected by the other AFS cells. 
Indolamine 2,3 dioxygenase (IDO) pathway was not significantly involved in 1st trimester-
AFS cells-mediated T cell suppression, while it was the main inhibitory mechanism in 2nd 
and 3rd trimester-AFS.  
Overall, this study revealed a number of significant qualitative and quantitative differences 
among AFS cells of different gestational age in terms of phenotype, immunological 
functions and immunogenicity, which all have to be taken into consideration in view of AFS 
cell clinical application. 
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INTRODUCTION 
 
 
Stem cell-based regenerative medicine, aimed at generating biological substitutes and 
improving tissue functions (tissue engineering), has been recently suggested as a 
potential alternative to current therapeutic modalities, such as medical therapy, surgery, 
organ transplantation, and mechanical devices. Three essential factors are necessary for 
tissue engineering: stem cells retaining the capacity to self-renew and restore damaged 
tissues due to their high ability to proliferate and differentiate; the use of scaffolds 
supporting stem cell survival, proliferation and differentiation; the use of growth and 
differentiation factors to favor stem cell functions. 
Stem cells isolated from adults or developing embryos (embryonic stem cells) are currently 
considered a source of cells for regenerative medicine. However, despite their therapeutic 
potential, both adult and embryonic stem cells present a number of limitations to their 
clinical application1. For instance, not always an adequate number of autologous adult 
stem cells can be easily achieved from the patient. On the other hand, human embryonic 
stem cells can quickly proliferate in culture and differentiate into a large number of adult 
tissues, but their growth is still poorly prone to be controlled and leads inevitably to tumor 
formation; in addition, the expression of embryonic and fetal antigens may elicit immune 
alloreaction and graft rejection; furthermore, the ethical issues related to the use of 
embryos are still unsolved, although some promising improvements will probably come 
from the use of induced pluripotent stem cell (iPSC) technology. 
Fetal stem cells are a relatively new source in the field of stem cell research, exhibiting 
unique and fascinating features belonging to both embryonic and adult stem cells, and 
therefore representing a new putative strategy for regenerative medicine. These cells can 
be obtained from the fetus or extra embryonic tissues, such as amniotic fluid2 [Figure1]. 
The latter represent an appealing choice due to easiness of cell harvesting during 
pregnancy without affecting fetal tissue integrity. 
 
 
AMNIOTIC FLUID 
 
Amniotic fluid allows the fetus to freely grow and move inside the uterus and acts as a 
vehicle for the exchange of body chemicals with the mother. In humans, the amniotic fluid 
starts to appear at the beginning of week 2 of gestation as a small film of liquid between 
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the cells of the epiblast. Between days 8 and 10 after fertilization, this fluid gradually 
expands and separates the epiblast from the amnioblast, thus forming the amniotic cavity. 
Thereafter, it progressively increases in volume, completely surrounding the embryo after 
week 4 of pregnancy. Over the course of gestation, amniotic fluid volume changes 
markedly from 20 ml in week 7 to 600 ml in week 25, 1.000 ml in week 34 and 800 ml at 
birth. During the first half of gestation, the amniotic fluid results from the active sodium and 
chloride transport across the amniotic membrane and the non-keratinized fetal skin, with 
concomitant passive movement of water. In the second half of gestation, the amniotic fluid 
is represented by fetal urine, gastrointestinal excretions, respiratory secretions and 
substances exchanged through the sac membranes.3  
The amniotic fluid is primarily composed of water and electrolytes (98-99%) but also 
contains chemical substances (e.g. glucose, lipids, proteins, hormones and enzymes), 
suspended materials (e.g. vernix caseosa, lanugo hair and meconium) and cells.  
Cells begin to appear in the amniotic fluid at about 14 weeks of gestation and the total 
number increases steadily during pregnancy, although the proportion of viable cells 
decreases. Amniotic fluid cells derive both from extra-embryonic structures (i.e. placenta 
and fetal membranes) and from embryonic and fetal tissues. Although amniotic fluid cells 
are known to express markers of all three germ layers, their origin is still debated; they 
mainly consist of cells shed in the amniotic cavity from the developing skin, respiratory 
apparatus, urinary and gastrointestinal tracts. [Figure 2A] Amniotic fluid cells display a 
broad range of shapes and functions, varying with gestational age and fetal development. 
In normal conditions the number of amniotic fluid cells increases with gestation; if a fetal 
disease is present, amniotic fluid cell counts can be either dramatically reduced (e.g. 
intrauterine death and urogenital atresia) or abnormally elevated (e.g. anencephaly, spina 
bifida and exomphalos). On the basis of their morphological and growth characteristics, 
viable adherent cells from the amniotic fluid are classified into three main groups: 
epithelioid (33.7%), amniotic fluid specific cells (60.8%) and fibroblastic type cells (5.5%). 
In the event of fetal abnormalities, other cell types can be found in the amniotic fluid, e.g. 
neural cells, in presence of neural tube defects, and peritoneal cells, in case of abdominal 
wall malformations. The majority of cells in the amniotic fluid is terminally differentiated and 
has limited proliferative capacity. In the 1990s, however, two groups demonstrated the 
presence of a small subset of cells in the amniotic fluid harboring proliferation and 
differentiation potential. First, Torricelli et al.4 reported the presence of hematopoietic 
progenitors in the amniotic fluid collected before week 12 of gestation. Then, Streubel et 
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al.5 achieved differentiation of amniotic fluid cells into myocytes, thus suggesting the 
presence in the amniotic fluid of non-hematopoietic precursors. These results triggered 
new interest in the amniotic fluid as an alternative source of cells for therapeutic 
applications. 
 
AMNIOTIC FLUID STEM CELLS 
 
Originally, the German biologist Haeckel in 1868 used the term ‘stem cell’ -stammzelle- to 
define the unicellular ancestor cell of all multicellular organism develop.6 
Presently, only the zygote up to 1-3 days after fertilization is considered totipotent, i.e. 
capable of giving rise from each cell to identical complete individuals consisting of 
complete embryonic and extra-embryonic tissues. After that point, blastocystis develops 
and differentiation capability declines towards pluripotency in the inner cell mass (i.e. 
capability of differentiating into tissues of 2 or 3 germ layers) and then multipotency after 
birth in adult stem cells (i.e. capability of differentiating into different tissues belonging to 
only 1 germ layer). Fetal stem cells may be considered in-between as far as their 
differentiation potential is concerned. Although amniotic membrane and amniotic fluid are 
physically separate, cells from the amniotic membrane can be found in the amniotic fluid 
and will be here referred to as amniotic fluid stem cells. Amniotic membrane may be 
collected during villocentesis at the first trimester or after delivery, while amniotic fluid is 
achievable through amniocentesis for prenatal diagnosis between 15th and 20th week and 
after cesarean section 7. 
The first evidence that the amniotic fluid could contain pluripotent stem cells was provided 
in 2003 by Prusa et al.8, who described the presence of a distinct sub-population of 
proliferating amniotic fluid cells (0.1-0.5%) expressing the pluripotency marker Oct4 
(octamer, binding transcription factor 4) at both transcriptional and protein levels, as well 
as MSCs markers, such as CD90, CD105, CD73, CD166, while lacking hematopoietic 
markers, such as CD45, CD34, CD14. Oct4 is a nuclear transcription factor that plays a 
critical role in maintaining embryonic stem cell differentiation potential and self-renewal 
capacity.9 Besides embryonic stem cells, Oct4 is specifically expressed by germ cells, 
where its inactivation results in apoptosis, and by embryonic carcinoma cells and tumors of 
germ cells origin, where it acts as an oncogenic fate determinant. While its role in stem 
cells of fetal origin has not been completely addressed, it has been recently demonstrated 
that Oct4 is neither expressed nor required by somatic stem cells and progenitors10. 
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Nevertheless, different groups confirmed the expression of Oct4 and its transcriptional 
targets (e.g. Rex-1) in the amniotic fluid11. 
Remarkably, Karlmark et al.12 transfected human amniotic fluid cells with the green 
fluorescent protein gene under either Oct4 or Rex-1 promoter and found that some 
amniotic fluid cells were thus capable of activating these promoters. Several authors 
subsequently harvested amniotic fluid cells displaying features of pluripotent stem cells13. 
Thereafter, the presence of a cell population capable of generating clonal cell lines 
differentiating into lineages representative of all three embryonic germ layers was 
definitively demonstrated14 [Figure 2B]; these cells were not tumorigenic, retained long 
telomeres, and maintained a normal karyotype for over 250 population doublings.14 
Amniotic fluid stem cells are characterized by the expression of the surface antigen c-kit 
(CD117), the type III tyrosine kinase receptor of the stem cells factor.15.  
Maguire et al., in search of markers defining the origin of amniocytes, performed in a large 
number of samples immunostaining, flow cytometry, clonal analysis, qPCR and RNA-seq 
whole genomic profiling 16. After clonal analysis, most of the amniotic fluid samples were 
positive for the transcription factor OCT4 (at cytoplasmic and nuclear level), SOX2, 
NANOG, KLF and WDR5, a key factor that interacts with OCT4. The expression pattern of 
SSEA1, SSEA3, SSEA4, TRA1-60 and TRA1-81 was heterogeneous, as a large cell 
population was positive for SSEA4, while a smaller cell group was double positive for 
SSEA1/SSEA4, Tra1-60/SSEA4 and TRA1-81/SSEA4. The peculiar, broad differentiation 
potential of amniotic fluid stem cells is shown by the co-staining of more than 75% of these 
cells with at least two multilineage surface proteins, such as SOX17 endodermal marker, 
SM22α mesodermal (smooth muscle) marker and Tubb3 ectodermal (neuronal) marker. A 
recent study reported that c-Kit+ Lin- cells derived from human amniotic fluid may display a 
multilineage differentiation potential in vitro also towards the hematopoietic lineages17. 
 
DIFFERENTIATION 
Amniotic fluid stem cells display multi-differentiation capabilities towards tissues or organs 
deriving from all the three embryonic germ layers14,18. 
ENDODERM 
To induce liver-specific differentiation, amniotic fluid stem cells were cultured in medium 
containing hepatocyte growth factor, insulin, oncostatin M, dexamethasone and fibroblast 
growth factor-4. Consequently, they displayed the expression of albumin, transcription 
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factor HNF4α, c-met receptor MDR membrane transporter and α-fetoprotein18. The 
potential for lung-specific differentiation was also revealed by ex vivo culture of human 
amniotic fluid stem cells in mouse embryonic lungs, where injected cells could integrate 
into the epithelium and express the thyroid transcriptional factor 1, an early human 
differentiation marker 19 
ECTODERM 
Amniotic fluid stem cells can be induced to differentiate into neuron-like cells through 
culture in medium containing dimethyl sulfoxide, butylated hydroxyanisole and neuronal 
growth factor. During the differentiation culture, amniotic fluid stem cells change their 
shape into large, flat, small and bipolar cell types, which is followed by the appearance of 
cone-like terminal expansions and expression of neural-specific proteins, including 
neuroepithelial and neuronal markers as well as some glial markers14. 
MESODERM 
Myogenic differentiation can be induced by treating amniotic fluid stem cells with 5-
azacytidine and then culturing them on Matrigel® -coated culture dishes, in medium 
supplemented with horse serum and chick embryo extract. Differentiated cells form 
myotubules and express sarcomeric tropomyosin and desmin, whereas these markers are 
not expressed in the original progenitor cell population14. Adipogenic differentiation is 
induced in media containing 3-isobutyl-1-methyl-xanthine, insulin and indomethacin, as 
confirmed by accumulation of intracellular lipid-rich vacuoles14. 
Endothelial differentiation can be induced by culturing amniotic fluid stem cells on dishes 
coated with gelatin in endothelial basal medium, which contains epithelial growth factor, 
vascular endothelial growth factor, fibroblast growth factor 2, insulin-like growth factor 1, 
hydrocortisone, heparin and ascorbic acid. This treatment induced the expression of 
human specific endothelial cell surface markers, such as factor VIII and kinase inert 
domain-containing receptors, as well as morphological changes, such as cobblestone and 
capillary-like structures on 2 and 3 dimensional culture substrates, respectively14. 
Osteogenic differentiation can be induced by media containing dexamethasone, β-
glycerophosphate and ascorbic acid-2-phosphate, as confirmed by calcium precipitation 
and alkaline phosphatase activity 14. 
Chondrogenic differentiation can be induced by culturing cell pellets on alginate hydrogel 
with media containing dexamethasone, ascorbic acid-2-phosphate, sodium pyruvate, 
proline and transforming growth factor-β1, thus showing sulfated glycosaminoglycan and 
type II collagen expression 20. 
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IMMUNOPHENOTYPE 
Amniotic fluid stem cells exhibit a typical MSC marker expression, such as CE90, CD73, 
CD105, CD29, CD166, CD49e, CD58 and CD44, as determined by flow cytometry 13,21,22. 
Additionally, cells express class I HLA antigens, but not hematopoietic markers (CD34 and 
CD45), endothelial markers (CD31), and class II HLA molecules. 13,21,23. More importantly, 
most cultured amniotic fluid mesenchymal stem cells (MSC) express pluripotency markers, 
such as the Oct4, the homebox transcription factor Nanog, and SSEA-4 13,14,21. 
Actually, amniocytes contain also a small population of CD117-positive cells that can be 
clonally expanded in culture14. The differentiation properties of CD117+ amniotic fluid stem 
cells were tested for the first time in vivo, thus proving their stem cell nature14. Amniotic 
fluid stem cells seem to derive from spindle-shaped fibroblastoid cells 24. 
In a recent study Moorefield et al. demonstrated that direct contact with amniotic fluid stem 
cells inhibits lymphocyte activation; similar results were obtained with cell-free 
supernatants derived from amniotic fluid stem cells primed with total blood monocytes or 
IL-1β (a cytokine released by monocytes and essential in mediation of the inflammatory 
response). Further investigation with amniotic fluid stem cell-free supernatants by protein 
array revealed the secretion of multiple factors shared by MSCs that are involved in 
immune regulation, including growth-related oncogene and monocyte chemotactic protein 
family members, as well as IL-6. Amniotic fluid stem cells activated by peripheral blood 
mononuclear cells release several additional cytokines, as compared to bone marrow 
MSCs, including macrophage inflammatory protein-3α, MIP-1α and Activin. Amniotic fluid 
stem cells also released higher level of MCP-1 and lower level of MCP-2 compared to 
bone marrow MSCs, in response to IL-1β activation. This suggest that there may be some 
amniotic fluid stem cells specific mechanism of inhibition of lymphocyte activation25. 
In an attempt to analyze amniotic fluid stem cells subpopulations, Roubelakis et al. 
identified recently two morphologically distinct population of amniotic fluid stem cells of 
mesenchymal origin, with different proliferation and differentiation properties, termed as 
spindle-shaped an round-shaped 26. Both subsets express MSC markers at similar levels. 
However, spindle-shaped colonies expressed higher levels of CD90 and CD44 antigens, 
as compared to round-shaped colonies. 
Recently, our group applied highly standardized methods to compare the immunological 
properties of human bone marrow MSCs, olfactory ectomesenchymal stem cells, 
leptomeningeal stem cells, and three different c-Kit-positive stem cells, i.e. cardiac stem 
cells, lung stem cells and amniotic fluid stem cells. We found that all these stem cell types 
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share a common pattern of immunological features, including expression of activation 
markers (ICAM-1, VCAM-1, HLA-ABC, and HLA-DR), modulatory activity towards purified 
immune effectors (T, B, and NK cells), lower immunogenicity following priming with 
inflammatory cytokines as compared to the resting conditions, and molecular inhibitory 
pathways (mainly related to indoleamine-2, 3-dioxygenase-activation). Moreover, all the 
stem cell types analyzed exert an anti-apoptotic effect towards resting immune effector 
cells, thus showing that the inhibitory effect is not a constitutive property of stem cells, but 
it is acquired as a consequence of immune effector cell activation.27  
TRANSCRIPTOMICS 
A functional analysis of the gene expression signature of amniotic fluid MSCs, as 
compared to bone marrow, cord blood and amniotic membrane MSCs, was initially 
performed by Tsai et al.28. Genes expressed in MSCs from all the three sources could be 
categorized in groups related to (i) extracellular matrix remodeling and tissue inhibitor 
metalloproteinase 1, (ii) cytoskeletal regulation, (iii) chemokine regulation and adhesion, 
(iv) plasmin activation, (v) transforming growth factor β receptor signaling and (vi) genes 
encoding E3 ubiquitin ligases28. The upregulated genes in amniotic fluid MSCs, as 
compared to bone marrow, cord blood and amniotic membrane MSCs, included molecules 
involved in uterine maturation and contraction, such as oxytocin receptor and regulation of 
prostaglandin synthesis, such as phospholipase A2. Other upregulated genes in this group 
were involved in signal transduction related to (i) thrombin triggered response, (ii) 
hedgehog signaling, and (iii) G-protein related pathways, regulator of G protein signaling 5 
and 7, and phospholipase C beta 428. 
Recently, Kim et al. described for the first time by illumine microarray analysis the gene 
expression changes in total amniotic fluid stem cells population during different passages; 
1970 differentially expressed genes were detected and categorized according to their 
expression profiles into 9 distinct clusters29. Genes with gradually increasing expression 
levels included chemokine ligand 12, cadherin 6, and folate receptor 3. Down-regulated 
genes included cyclin D2, keratin 8, IGF2, natriuretic peptide precursor B and cellular 
retinoic acid binding protein 2.29. To obtain further information, chip data analysis on aging 
genes was performed and revealed the up-regulation of gene transcripts, such as nerve 
growth factor beta, insulin receptor substrate 2, insulin-like growth factor binding protein 3 
and apolipoprotein 3. 
Wolfrum et al. performed a global gene expression analysis of amniotic fluid stem cells 
compared to iPSCs derived from amniotic fluid and embryonic stem cells.30. Among these, 
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genes related to self-renewal and pluripotency were detected in amniotic fluid stem cells30. 
Furthermore, the authors examined the expression of senescence and telomere-
associated genes in amniotic fluid stem cells of early and late expansion passages to 
study the effect of reprogramming on cell senescence. 64 genes were identified as 
differentially expressed in amniotic fluid stem cells, as compared to amniotic fluid iPSCs 
lines. Of these, telomere-associated and cell cycle-regulating genes were down-regulated 
in amniotic fluid stem cells, as compared to amniotic fluid-derived iPSCs and embryonic 
stem cells.30.  
Recently, Moschidou et al. used microarray-based transcriptome analysis to investigate 
whether 1st and 2nd trimester c-Kit+ amniotic fluid stem cells show similar gene expression 
profiles. These cell populations were related but differed as far as cell size and molecular 
signature were concerned, with a cell-specific gene expression signature including 366 
genes for 1st trimester and 340 genes for 2nd trimester amniotic fluid stem cells31. 
PROTEOMICS 
Proteomic studies on the total amniotic fluid stem cell populations, including epithelioid, 
amniotic fluid-specific and fibroblastic cells, revealed 2400 spots that resulted in the 
identification of 432 different gene products. The majority of the proteins was localized in 
the cytoplasm, mitochondria and nucleus and represented mainly enzymes and structural 
proteins. A relatively high percentage of membrane associated proteins were also 
present32. 
Recent studies provided evidence that the metabolic enzyme pattern in the amnion cells is 
involved in metabolic and genetic syndromes, thus their detection might be important for 
prenatal diagnosis. 
A proteomic analysis was also performed on different cultures passages of CD117+ 
amniotic fluid stem cells, exhibiting variations in protein expression that mainly occurred in 
early passages. 23 proteins were differentially expressed between early and late 
passages33. 
In 2007, the proteomic map of human amniotic fluid MSCs was drawn and directly 
compared to the one derived from bone marrow MSCs21. 261 different proteins were 
identified in amniotic fluid MSCs with the majority of proteins localized in the cytoplasm. 
Amniotic fluid MSCs expressed a number of proteins related to proliferation and cell 
maintenance, such as ubiquilin-1 (controlling cell cycle progression and cell growth), the 
proliferation-associated protein 2G4 (a nucleolar growth regulating protein), the acidic and 
rich in cysteine secreted protein (regulated during embryogenesis and involved in the 
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control of cell cycle and cell adhesion).21. Other proteins expressed at high levels in 
amniotic fluid MSCs were related to development and cytoskeletal organization and 
movement. 
SECRETOME 
Recently, the analysis of the secreted proteins from amniotic fluid stem cells has 
significantly improved. Amniotic fluid stem cell secretome was responsible for enhancing 
vasculogenesis and capable of evoking a strong angiogenic response in murine 
recipient34. According to this study, a detailed analysis with Luminex’s MAP Technology of 
the amniotic fluid stem cell-conditioned media revealed the presence of proangiogenic and 
antiangiogenic factors. Vascular endothelial growth factor, stromal cell-derived factor 1, 
interleukin 8, monocyte chemotactic protein 1, and two angiogenesis inhibitors, interferon-
gamma and interferon-gamma induced protein 10, were identified as secreted proteins. 
34,35. 
It was also demonstrated that a relative small number of amniotic fluid stem cells was 
enough to secrete a detectable amount of proangiogenic growth factors and cytokines. 
A systematic study on amniotic fluid stem cells-secreted proteins led to the conclusion that 
proangiogenic soluble factors from amniotic fluid stem cells can mediate the recruitment of 
endothelial progenitors in an ischemic rat model36. 
In a recent study, the therapeutic potential of an amniotic fluid MSCs and their secreted 
molecules was studied in mice with acute hepatic failure37. A variety of cytokines and 
growth factors were detected in amniotic fluid MSCs medium. Different cytokines were 
shown, such as interleukin 10, interleukin 27, interleukin 17 families, interleukin 12p70, 
interleukin-1β and interleukin-1 receptor antagonist, responsible for inducing local and 
systemic down-regulation of pro-inflammatory mediators. In addition, SERPINE1, MCP-1 
and SDF-1 responsible for promoting tissue repair, were also detected.  
 
  
	   12	  
AIM OF THE PROJECT 
 
Stem cells can be found in different tissues at various developmental stages; however, the 
phenotype of stem cells originating from the same tissue source may vary according to the 
development stage at which they are isolated.  
AFS cells as well as other stem cells derived from different tissues display immune 
modulatory properties as a common feature. AFS cells can be collected at different 
gestational age and their phenotype and differentiation potential seems to depend on fetal 
development. The differences in gene profile between 1st and 2nd trimester-AFS cells have 
been recently investigated by means of microarray-based transcriptome analysis. 
However, the assessment of immune modulatory capabilities of AFS cells at different 
gestational age is still lacking.  
In this study, we used standardized approaches to investigate the immunological profile of 
AFS cells isolated at different gestational age, including phenotypic analysis, 
immunogenicity and immunomodulatory functions towards various immune effector cells 
(IECs). 
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METHODS 
 
  
AMNIOTIC FLUID STEM CELLS 
Amniotic fluid was collected at different weeks of gestation with to isolate and analyze AFS 
cells. AFS cells (four samples for 1st and 2nd trimester and five for 3rd trimester) were 
achieved from human amniocentesis carried out for diagnostic purposes (cytogenetic 
analysis) between 10-12 weeks of gestation for 1st trimester-AFS cells, between 16-18 for 
2nd trimester-AFS cells and between 38-40 for 3rd trimester-AFS cells, after mother’s 
informed consent. 
Cells adhering to flasks were expanded in Chang B+C medium. Cluster of cells with 
mesenchymal-like morphology were harvested and immediately subjected to 
immunoselection, as previously reported14. Sorted c-Kit positive AFS cells were cultured in 
α-MEM medium (Gibco) containing heat-inactivated adult bovine serum, 100 U/mL 
penicillin, and 100 mg/mL streptomycin (all from Gibco), supplemented with 18% Chang B 
and 2% Chang C (Irvine Scientific). Full characterization of AFS cells has been already 
described by other groups elsewhere14. 
AFS cells were detached (0.05% Trypsin-EDTA; Gibco) and harvested when 80% 
confluent, and then either reseeded at 103/cm2 concentration or frozen until use. All 
experiments were performed between passages 2 and 10. 
 
IMMUNOPHENOTYPING 
AFS cells at 80% confluence were treated or not for 40 hours with 10 ng/mL IFN-γ and 15 
ng/mL TNF-α (R&D Systems). The lack of cytotoxic effects of this inflammatory cytokines 
was previously demonstrated38. To assess the specific expression of different markers, 
rested and primed AFS cells were labeled with the following monoclonal antibodies 
against human markers: IgG1k-PE, CD31-PE, CD34-PE, CD45-PE, CD73-PE, CD90-PE, 
CD105-PE, CD146-PE, CD107a-PE, CD54-PE, CD86-PE, CD106-PE, CD200-PE, and 
HLA-ABC-PE all from BD Biosciences; IgG1k-PE, CD80-PE, NG2-PE, IgG1k-FITC, and 
HLA-DR-FITC all from Beckman Coulter; IgG1k-PE, CD112-PE, CD155-PE, IgG2b-PE, 
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and CD274-PE all from Biolegend; IgG1-PE, IgG2a-PE, IgG2b-PE,  unconjugated IgG2a, 
normal goat IgG unconjugated, MICA/B-PE, ULBP-1-PE, ULBP-2-PE, CCR7-PE, CXCR3, 
CXCR5 and unconjugated ULBP-3 all from R&D Systems, IgG1-FITC and HLA-G from 
Exbio, IgG2a k-PE, IgG1-PE, TLR-4 PE, CD178_PE (FasL) from eBioscience, goat- anti-
mouse-PE from DAKO and donkey-anti-goat-PE from Abcam.  
105 AFS cells were incubated with the selected monoclonal antibody or appropriate 
isotype control in PBS for 15 min at room temperature. For ULBP-3 and Jagged-1 
expression, PE- conjugated goat anti-mouse IgG F(ab’)2 and PE-conjugated donkey 
F(ab’)2 polyclonal secondary antibodies were added, after incubating the cells with the 
primary unconjugated antibody. ULBP-1 expression was validated by intracellular staining 
using the Cytofix/Cytoperm kit (BD Biosciences) according to manufacturer’s instruction. 
Data were analyzed by FACSCanto II (BD Biosciences) and expressed as the ratio of 
geometric mean fluorescence intensity (rMFI) obtained for each marker and its isotype-
matched negative control. 
 
PROLIFERATION AND SURVIVAL ASSAYS 
IECs (CD3pos T cells, CD19pos B cells, and CD56pos NK cells) were purified from peripheral 
blood using appropriate negative selection kits (Miltenyi Biotech) and their purity (at least 
95%) was assessed by FACS analysis. 
To evaluate the immunomodulatory capabilities of AFS cells towards IEC proliferation, 
rested and primed AFS cells were cultured with purified T, B and NK cells at either 2x104 
cell concentration (high ratio, corresponding to a confluent monolayer), or 2x103 cell 
concentration (low ratio). Following AFS cells adhesion, 2x105 T cells, 2x104 B cells, or 
2x104 NK cells previously stained with 5 mM carboxyfluorescein succinimidyl ester (Life 
Technologies) were added. All IECs were activated by use of specific molecules. In 
particular, T cells were activated with 0.5 mg/mL cross-linking anti-CD3 and anti-CD28 
antibodies (Sanquin) for 6 days in Roswell Park Memorial Institute medium (RPMI) 
supplemented with 10% human AB serum. B cells were activated with 2 mg/mL F(ab’)2 
anti-human IgM/IgA/IgG (Jackson Immunoresearch), 20 IU/mL rhIL-2 (Proleukin; Novartis), 
50 ng/mL polyhistidine-tagged CD40 ligand, 5 mg/mL anti-polyhistidine antibody (R&D 
Systems), and 2.5 mg/mL CpG B (Invivogen) for 4 days in RPMI supplemented with 10% 
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FBS (Invitrogen Life Technologies). NK cells were activated by 100 IU/mL rhIL-2 for 6 days 
in Iscove modified Dulbecco medium (IMDM) supplemented with 10% human AB serum. 
At the end of co-culture, cells were harvested and labeled with PerCP mouse anti-human 
CD45 monoclonal antibody (BD Biosciences) and TOPRO-3 Iodide (Invitrogen Life 
Technologies); the percentage of proliferating cells was evaluated among viable TOPRO-
3negCD45pos cells by FACS analysis as the percentage of cells undergoing at least one cell 
division. The effect on the proliferation rate was obtained according to the following 
formula: (number of CD45pos cells in co-culturing conditions/ number of CD45pos cells 
alone) x100. 
To further understand which molecules were involved in immunomodulation, the following 
specific inhibitors were added to co-cultured AFS and T cells: 1 mM L-N-monomethyl 
arginine (L-NMMA) inhibitor of inducible NO synthase (iNOS); 5 mM NS-398  (Cayman 
Chemicals) inhibitor of cyclooxygenase-2 (COX-2) that is necessary for PGE2 synthesis; 
1mM L-1- methyl tryptophan (L-1MT) IDO inhibitor (Sigma-Aldrich); 2 mM tin-
protoporphyrin (SnPP) inhibitor of HO-1 (Frontier Scientific); and 10 mg/mL purified anti-
human IFN-g NA/LE mouse IgG1 (BD Biosciences). 
To determine the effect of AFS cells on IEC survival, resting and primed AFS cells were 
cultured with IECs at the same concentration described above for the immunomodulatory 
assays. The analysis of IEC apoptosis was performed after either 4 days (B and NK cells) 
or 6 days of co-culture (T cells). Cells were detached by trypsin and stained with 
Allophycocyanin (APC) mouse anti-human CD45 BD Biosciences and IEC apoptosis was 
assessed following manufacturer’s instructions (PE active caspase-3 apoptosis kit; BD 
Biosciences). Briefly, first the cells were fixed and permeabilized and then labeled with PE-
anti-caspase-3 antibodies and cell apoptosis was assessed as percentage of active- 
caspase-3negCD45pos viable cells by FACS analysis. 
 
IMMUNOGENICITY ASSAY 
AFS cell immunogenicity was assessed by using a non-radioactive cytotoxicity assay, 
following manufacturer’s instructions (Delfia Cytotoxicity kit; Perkin Elmer). NK cells were 
stimulated for 48 hours with 100 IU/mL rh-IL-2 and used as effector cells. AFS cells were 
labeled with bis-acetoxymethyl terpyridine dicarboxylate (BATDA) fluorescent dye, and 
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used as target cells in co-culture with previously activated NK cells at different ratios 
(ranging from 1:1 to 50:1, corresponding to NK:AFS ratio). After 1 hour, the cytotoxicity 
was quantified by assessing fluorescence release in co-culture supernatants by a time-
resolved fluorimeter (VictorTM X4, Perkin Elmer). 
 
STATISTICAL ANALYSIS 
Data were expressed as mean ± standard deviation, except for immunophenotype data 
that were expressed as mean ± standard error of the mean. Statistical analysis was 
performed by Prism software (GraphPad) using the Wilcoxon test to compare the effect of 
priming on the same AFS cells, while one-way ANOVA test was used to assess the 
differences among AFS derived from different trimesters. P <0.05 was considered 
statistically significant. 
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RESULTS 
 
 
 
MORPHOLOGICAL AND IMMUNOPHENOTIPIC DIFFERENCES AMONG AFS CELLS 
 
Before focusing our attention on the immunological behaviors of AFS cells, we 
characterized the AFS cells in term of morphology and expression of typical specific 
markers. In all experiments, cells were cultured at the same condition and used at the 
same passages. All different types of AFS cells showed their canonical morphologies 
(Figure 3A). 1st and 2nd trimester-AFS cells displayed a fibroblast-like shape, while 3rd 
trimester-AFS cells were more heterogeneous, showing often an oval-round shape. The 
immunophenotypical analysis revealed a similar pattern of expression but with some 
peculiarities (Figure 3B). Hematopoietic markers, CD31, CD34, and CD45 were 
undetectable in all AFS cells with the exception of resting 1st trimester-AFS cells, which 
weakly expressed CD34. In contrast, mesenchymal markers were detectable in all AFS 
cells. CD73 was highly expressed in 3rd trimester-AFS and modestly present in the others 
AFS types. All AFS cells showed a strongly expression of CD90, particularly by 1st and 3rd 
trimester-AFS cells, while the CD105 was weakly expressed by all AFS cell types. The 
expressions of neuron-glial antigen 2 (NG2) and melanoma cell adhesion molecule 
(CD146) were also evaluated. NG2 was highly expressed in 1st trimester-AFS cells, 
moderately in 3rd trimester-AFS cells and poorly in 3rd trimester-AFS cells. CD146 was 
slightly detected in 1st and 2nd trimester-AFS cells, while 3rd trimester-AFS cells showed 
the higher expression of this marker.  
 
 
EFFECT OF INFLAMMATORY PRIMING ON AFS CELLS 
 
With the aim to understand whether the gestational age could affect the 
immunomodulatory capabilities of AFS cells, all AFS cells were treated or not with IFN-γ 
and TNF-α, in order to mimic the inflammatory milieu. 
First, we evaluated the expression of different molecules involved in MSC 
immunomodulation (Figure 4). HLA-ABC expression of 1st trimester AFS cells were 
significantly different from that observed in other AFS cells (P<0.05). At resting conditions, 
1st trimester-AFS cells showed lower expression of HLA-ABC, while 2nd and 3rd trimester-
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AFS cells displayed a moderate expression of this molecule. Interestingly, after 
inflammatory priming, HLA-ABC expression increased in all AFS cell types. This 
overexpression was reduced in 1st trimester-AFS cells (1.87-fold) as compared to 2nd and 
3rd trimester-AFS cells, where the fold-change resulted significantly higher (2.23-fold, 2.15-
fold respectively). Moreover, also in priming conditions, AFS cells maintained the 
significant differences observed at baseline (P<0.05). HLA-DR was never expressed at 
resting conditions, but following treatment with inflammatory cytokines we observed a 
slight overexpression of this molecule in all AFS cell types. The co-stimolatory molecules 
CD80 and CD86 were never detectable in all AFS cell types. In contrast, CD40 molecule 
was scarcely expressed only by 2nd and 3rd trimester-AFS cells, and only in the latter case 
the inflammatory priming significantly modulated this expression. We tested the 
expression of CD54 (ICAM-1), CD106 (VCAM-1), which belong to cell adhesion molecule 
(CAM) family and are involved in different cell mechanisms, such as migration, tethering 
on IEC surface and modulation of inflammation39. In control condition, CD54 was fairly 
expressed in 1st and 2nd trimester-AFS cells and less in the other AFS cells. However, 
following inflammatory priming, CD54 was significantly up regulated in 1st (22.17-fold), 2nd 
(11.53-fold) and 3rd (65.62-fold) trimester AFS cells. CD106 was not particularly expressed 
at baseline, but the inflammatory cytokines induced the increase of this adhesion molecule 
that was more evident in 2nd and 3rd trimester AFS cells. Finally, we assessed the 
expression of two immunosuppressive molecules, i.e. CD274 (PD-L1) and CD200, which 
are involved in modulation of T cell proliferation 40-42. At baseline, CD274 was expressed in 
all AFS cells, especially in 2nd and 3rd trimester AFS cells. Moreover, following priming a 
significant increased of CD274 expression was observed in all AFS cells (4.04-fold, 3.06-
fold and 3,2-fold respectively). Conversely, CD200 molecules were scarcely expressed 
only in 2nd trimester AFS cells, but inflammatory priming did not modulate this marker. 
Further analysis of different markers were performed to better characterized the different 
types of AFS cells, both at resting and primed conditions, and the mean ± SEM of relative 
Mean Fluorescence Intensity (rMFI) are reported in Table I. 
 
Then we assessed the immunomodulatory properties of AFS cells on different IECs. To 
this purpose, resting and primed AFS cells were co-cultured with purified T, B and NK cells 
at different ratios pre-stimulated or not. None of AFS cell types activated resting IECs 
(data not shown), in agreement to the insufficient expression of HLA class II and co-
stimulatory molecules (Figure 4). AFS cells did not show modulatory effects on IECs at 
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low ratio (100:1 for T cells, 10:1 for B and NK cells), except for 1st trimester-AFS cells. 
Conversely, at high ratio (10:1 for T cells, 1:1 for B and NK cells), all AFS cells displayed 
different immunomodulatory capabilities in presence of pre-stimulated IECs. Both resting 
and primed 1st trimester-AFS cells inhibited T cell proliferation by more than 80% at high 
ratio, and showed almost 30% of inhibition at low ratio (Figure 5A). AFS cells derived from 
2nd and 3rd trimester exhibited a lower immunosuppressive effect on T cell proliferation in 
respect to 1st trimester-AFS cells, and only primed 3rd trimester-AFS cells showed a 
significant inhibition. Similarly, 1st trimester-AFS cells had the higher immunosuppressive 
effect on NK cell proliferation respect to other AFS cells that instead exhibited a weak 
suppression (Figure 5B). None of AFS cells affected B cell proliferation at baseline 
(Figure 5C). This effect was related to the inability of B cells to release IFN-γ, the main 
cytokine involved in MSC activation43. At baseline, 1st and 3rd trimester AFS cells had a 
trophic effect towards B cells, showing a slight increase of B cell proliferation. Conversely, 
resting 2nd trimester AFS cells failed to modulate B cell proliferation, but following priming 
they showed a strongly immunosuppression effect, which was never shown by other AFS 
cells. 
 
MOLECULAR MECHANISMS INVOLVED IN T CELL IMMUNOSUPPRESION 
 
Next, we explored the molecular mechanisms underlying the immunosuppressive effect of 
AFS cells on T cell proliferation. To this purpose, we tested the effects of different 
inhibitors of the main molecules involved in immunosuppression. In particular, we inhibited 
the function of IDO, iNOS, COX-2, HO-1 and IFN-γ by specific inhibitors and neutralizing 
anti-IFN-γ antibody. All the inhibitors have been previously tested on MSCs27,44 at 
concentrations that do not alter T cell viability and proliferation. 
The crucial role that IDO plays in T cell immune suppression has been largely 
demonstrated by different groups45,46. When L-1MT was added to AFS-T cell cultures, a 
complete rescue of T cell proliferation was observed with resting and primed 2nd and 3rd 
trimester AFS cells (Figure 6). Surprisingly, 1st trimester AFS cells did not exhibit the 
same effect, probably due to a different mechanism of suppression. Moreover, 1st trimester 
AFS cells, which showed the highest immunosuppressive effect on T cell proliferation, 
displayed another peculiarity, i.e. they strongly induced cell death. In fact, at the end of 
AFS/T co-culture, we observed a low percentage of TOPRO-3negCD45pos cells, which 
instead was not altered in 2nd and 3rd trimester-AFS cells (Figure 7A). Although IDO 
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activity can elicit cell death as well as immune suppression and anergy, the cytotoxic effect 
of 1st trimester-AFS cells was probably associated with another immunosuppression 
mechanism, as demonstrated by the lack effect of L-1MT. To investigated whether this 
results could be related to a mechanism of apoptosis, we tested the expression of Fas 
ligand (FasL) on AFS cells, but none of cells did show this molecule (Figure 7B).  
The IFN-γ blocking antibody only partially rescued T cell proliferation (Figure 6), while the 
inhibitors LNMMA, NS-398 and snPP did not any effect on suppression of T cell 
proliferation (Figure 8).  
 
 
IFN-γ/TNF-α-STIMULATED AFS CELLS ARE REFRACTORY TO NK CYTOTOXICITY. 
 
With the aim to determine whether AFS cells were susceptible to NK-mediated lysis, 
BATDA-labeled AFS cells were used as target cells and cultured in presence of IL-2 pre-
stimulated NK cells at different NK:AFS ratios, which ranged from 1:1 to 50:1 (Figure 9A). 
At baseline, AFS cells were sensitive to NK-mediated lysis in a dose-dependent manner. 
Nevertheless, following inflammatory priming all AFS cells acquired resistance to NK 
cytotoxicity. Hypothesizing that these results were related to a different expression of NK 
ligands on AFS surface induced by priming, we performed an immunophenotype analysis 
(Figure 9B). We tested the expression of various NK cell-activating ligands, including 
Nectin-2 (CD112) and Poliovirus receptor (PVR, CD155), which bind the DNAX Accessory 
Molecule-1 (DNAM-1), the MHC Class I-related A and B molecule (MICA/B) and UL16-
binding proteins (ULBPs), which instead interact with NKG2D. CD112 and CD155 were 
constitutively expressed in all AFS cells. At resting condition, the expression of CD112 was 
higher in 3rd trimester AFS cells respect to other cells and its expression was enhanced 
after inflammatory priming, except for 1st trimester AFS cells. In control condition, CD115 
was strongly expressed in 2nd and 3rd trimester AFS cells and modestly present in 1st 
trimester AFS cells; however, a strongly up-regulation was observed following 
inflammatory priming in all AFS cell types. Finally, we tested the expression of ULBPs and 
MICA/B, which are the ligand of the NKG2D receptor. None of these activating ligands was 
particularly expressed by all AFS cell types, except for a moderate expression of ULBP-1 
in 1st trimester AFS cells and ULBP-2 and MICA/B in 3rd trimester AFS cells, but the 
priming did not alter significantly the levels of these proteins.  
The increase in AFS cells resistance to NK-mediated lysis could be associated to the 
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different expression of HLA-ABC, the crucial NK inhibitory ligand. It has been widely 
demonstrated that the overexpression of HLA class I prevails over NK activating ligands, 
leading to the inhibition of NK-mediated cytotoxicity47. It is important to point out that 
primed 1st trimester-AFS cells showed higher sensibility to NK cytotoxicity in respect to 
other AFS cells. This phenomenon is in agreement with the lower expression of HLA-ABC 
in 1st trimester AFS cells (Figure 4) and their higher expression of ULBP-1 and ULBP-2, 
both in resting and priming conditions. 
 
ANTI-APOPTOTIC EFFECT OF AFS CELLS ON RESTING IECs. 
 
We then assessed the effect of AFS cells on resting IECs. Normally, in absence of 
inflammatory stimuli, MSCs enhance immune cells survival48. Thus, to verify whether 
AFSs shared the same effects, resting and primed AFS cells were cultivated in presence 
of resting IECs at different ratios, and at the end of co-culture we evaluated their protective 
role towards IEC apoptosis. As previously shown for the immunosuppressive mechanism 
(Figure 5A-B), 1st trimester AFS cells displayed a different behavior towards T and NK 
cells (Figure 10A-B). Unlike the effects shown by other AFS cells, 1st trimester AFS cells 
did not increase T and NK cell viability. By contrast, 2nd and 3rd trimester displayed a 
significant supportive effect on T and NK cell viability. This trophic effect was less evident 
on T cell apoptosis, probably due to their greater resistance in culture alone as compared 
to NK and B cells; the latter lymphocyte population showed the highest percentage of 
caspase-3 positive cells when culture alone. However, a total rescue of B cell apoptosis 
was observed in presence of resting or primed AFS cells (Figure 10C). Finally, only in 
some cases we observed a dose-dependent anti-apoptotic effect, but these differences 
were never significant. 
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FIGURES 
 
 
 
 
 
Fig.1: Gestational tissues as a source of stem cells. Cell types with therapeutic potential 
can be derived from gestational tissues including the placenta, umbilical cord, amniotic 
fluid, and fetal membranes. 
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Fig. 2: Cell lineages identified in amniotic fluid (A); Multilineage differentiation of 
gestational stem cells. Stem cells from the amniotic fluid have been differentiated into a 
diverse range of cell types, including, but not limited to: neurons, hair and skin cells, 
pulmonary cells, cardiomyocytes, hepatocytes, pancreatic cells, osteocytes and 
adipocytes (B). 
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Fig. 3. Heterogeneity of AFS cells isolated at different gestational age. (A) Microscopy 
images showing morphologic differences among AFS cells analyzed (the scale bar 
indicates µm). All AFS cells were cultured in the same conditions and analyzed at the 
same passage. Images were obtained by Observer Z1, Zeiss. (B) FACS analysis of AFS 
cells showing the expression profile of typical hematopoietic and MSC markers. The 
histograms display the MFI (mean fluorescence intensity) of isotype controls (open curve) 
and specific markers (filled curve). Similar data were obtained in four (1st and 2nd trimester-
AFS cells) or five (3rd trimester-AFS cells) different donors. The mean ± SEM of relative 
MFI are reported in Table I. 
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Fig. 4. Expression of specific markers involved in immunomodulation. AFS cells were 
cultured with or without inflammatory cytokines, and after 2 days the expression of CD40, 
CD80, CD86, HLA-ABC, HLA-DR, CD200, CD274, CD54 and CD106 were evaluated by 
FACS analysis. The results are expressed as relative Mean Fluorescence Intensity (rMFI) 
± SEM of four (1st and 2nd trimester-AFS cells) or five (3rd trimester-AFS cells) different 
experiments. *P<0.05, **P<0.01, ***P<0.001.  
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Fig. 5. Immunomodulatory effect of different AFS cells on IEC proliferation. CFSE-labeled 
IECs activated with specific stimuli were cultured alone or in presence of resting and 
primed AFS cells. All experiments were carried out at different IEC:AFS ratios, i.e. 10:1 
and 100:1 for T cells (A), and 1:1 and 10:1 for both NK (B) and B cells (C) (high and low 
ratio, respectively). Data are represented as proliferation percentage of IECs 
corresponding to the mean ± SD of CFSE fluorescence of CD45pos TOPRO-3neg cells 
derived from 4 different experiments. *P<0.05, **P<0.01, ***P<0.001. 
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Fig. 6. Role of IDO and IFN-γ on T cell immunosuppression. CFSE-labeled T cells 
stimulated with anti-CD3 and CD28 were cultured alone or in presence of resting and 
primed AFS cells. L-1MT and an IFN-γ blocking antibody were added to co-cultures in 
order to evaluate the involvement of IDO and IFN-γ in AFS-mediated immunosuppression. 
At the end of co-culture (6 days) the cells were harvested and FACS analyzed the 
proliferation percentage. Data are represented as proliferation percentage of IECs 
corresponding to the mean ± SD of CFSE fluorescence of CD45pos TOPRO-3neg cells 
derived from 4 different experiments. *P<0.05, **P<0.01, ***P<0.001. 
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Fig 7. Cytotoxic effect of 1st trimester-AFS cells on activated T cells. (A) Data show the 
percentage of CD45posTopro3neg derived from T cell immunosuppression assays. (B) Flow 
cytometry analysis of AFS cells showing the expression Fas ligand. The histograms 
display the MFI (mean fluorescence intensity) of isotopic controls (open curve), and 
specific markers (filled curve) and the numbers within histograms represent the rMFI. 
A
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Fig. 8. Role of NS-398, snPP and LNMMA on T cell immunosuppression. CFSE-labeled T 
cells stimulated with anti-CD3 and CD28 were cultured alone or in presence of resting and 
primed AFS cells. The following specific inhibitors were added to T:AFS co-culture (as 
described in Materials and Methods): NS-398, the inhibitor of COX-2 (A), snPP, the 
inhibitor of HO-1 (B) and LNMMA, the inhibitor of iNOS (C). At the end of co-culture (6 
days) cells were harvested and proliferation rate was analyzed by FACS. Data represent 
the mean ± SD of CFSE fluorescence of CD45pos TOPRO-3neg cells derived from 4 
different experiments. 
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Fig. 9. Inflammatory microenvironment reduces AFS sensitivity to NK cell-mediated lysis. 
(A) IL-2 pre-stimulated NK cells were cultured in presence of BATDA labeled AFS cells at 
different ratios. AFCs were primed with IFNγ and TNFα (solid line) or not (grey line). The 
cytotoxic effect on resting and primed AFS cells were quantified as release of fluorescence 
by lysed cells and calculated by time-resolved fluorimeter (Victor X4 Multilabel Plate 
Reader, PerkinElmer). Data are showed as percentage of fluorescence release. Error bars 
represent the mean ± SD of four (1st trimester-AFS cells) or five (2nd and 3rd trimester-AFS 
cells) experiments.  
(B) AFS cells were cultured in presence or not of inflammatory cytokines. At day 2 the 
expression of CD112, CD155, MICA/B, and ULBPs was analyzed by FACS. The results 
are expressed as relative Mean Fluorescence Intensity (rMFI) ± SEM of four (1st and 2nd 
trimester-AFS cells) or five (3rd trimester-AFS cells) different experiments. *P<0.05, 
**P<0.01, ***P<0.001. 
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Fig. 10. Anti-apoptotic effect of AFS cells on resting IECs. Resting and primed AFS cells 
were cultured in presence of resting IEC at different ratios, i.e. 10:1 and 100:1 for T cells 
(A), and 1:1 and 10:1 for both NK (B) and B cells (C) (high and low ratio, respectively). At 
the end of co-culture (4 days for NK and B cells, 6 days for T cells, respectively) cells were 
harvested and labeled with anti-CD45 and anti-cytoplasmic caspase-3 antibodies to 
evaluate the IECs undergoing apoptosis. Data are expressed as percentage of caspase-
3negCD45pos cells and analyzed by FACS. Error bars represent the mean ± SD of four 
different experiments for 1st, 2nd and 3rd trimester-AFS cells. *P<0.05, **P<0.01, 
***P<0.001. 
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Table I. Expression of different markers on AFS cells derived from different gestational 
age. Resting and primed AFS cells were cultured in presence or not of IFN-γ and TNF-α 
for 48h. At the end of treatment, AFS cells were harvested and labeled with different 
antibodies (as reported in Materials and Methods). Data are shown as mean ± SEM of 
relative Mean Fluorescence Intensity (rMFI) of four (1st and 2nd trimester-AFS cells) or five 
(3rd trimester AFS cells) experiments derived from resting (upper) and inflammatory 
(below, bold) cells for each marker. 
1st 2nd 3th 1st 2nd 3th
NON  MSC MARKERS NKG2D LIGANDS
CD 31
1±0 1±0 1±0
ULPB-1
3.58±0.2 1.2±0.07 1.42±0.14
1±0 1.03±0.03 1±0 3.57±0.1 1.34±0.07 1.62±0.23
CD 34
1.57±0.4 1.1±0.06 1.1±0.1
ULPB-2
2.6±0.16 1.74±0.18 3.3±0.5
1.07±0.07 1.06±0.06 1±0 2±0.36 1.60±0.26 2.05±0.22
CD 45
1±0 1±0 1±0
ULPB-3
1.80±0.7 1.22±0.15 1.84±0.56
1±0 1.02±0.02 1±0 1.35±0.26 2.1±0.7 1.8±0.65
MSCs MARKERS
MICA/B
2.75±0.9 2.28±0.75 3.63±0.1
CD 73
41±5.97 37.5±10 86.6±30 1.65±0.23 1.77±0.43 2.5±0.9
43.3±8.47 35±8.37 86.06±25.54 TOLL-LIKE RECEPTORS
CD 90
339±92            95±69.37 328.3±71.3         
TRL 4
1.1±0.05 2.31±0.76 2.46±0.3
277.55±138.3 134.35±100.5 247.8±45.45 1.44±0.2 2.36±0.72 2.14±0.1
CD 105
4±0.53                2.82±0.4 4.14±1                IMMUNOMODULATORY 
MOLECULES
2.34±0.1 2.87±0.52 3.1±0.43
CD 200
1±0 2.17±0.97 1.1±0.3
COSTIMULATOTY 
MOLECULES 1±0 1.6±0.27 1±0
CD40
1.1±0.1 2.38±0.23 1.87±0.25
CD 274 (PD-L1)
13.85±3.7 24.76±5.54 26.5±6.6
1.1±0.1 3±0.5 2.9±0.5 56.05±7.2 75.85±19.2 86.5±13.8
CD 80
1.25±0.13 1±0 1.03±0 DNAM LIGANDS
1±0 1.02±0 1.03±0.02
CD 112
18.14±2.24 19.1±2.6 23.63±2.52
CD 86
1.1±0.1 1.1±0.05 1.36±0.16 18.3±1.9 27.24±4.53 36.37±8.4
1±0 1.15±0.15 1.06±0.04
CD 155
26.33±5.1 86.3±17.55 95.65±19.03
ADHESION MOLECULES 38.3±9.6 107±7.2 135±34.8
CD 54
23.45±10.22     25.53±8.9 11.1±4.63        MHC LIGANDS
519.95±57.04 582.7±52.65 728.44±17.9
HLA-ABC
4.18±0.6 7.9±1.07 12.04±2.67
CD 106
1.53±0.5 2.08±0.3 1.44±0.26 7.85±1.77 17.68±2.2 25.9±4.66
3.26±0.5 28.41±8.75 17.15±7.56
HLA-DR
1±0 1.1±0.06 1±0
CD 146
22.14±3.4 27.3±2 57.9±14.43 3.1±1.24 2.30±1.14 3.73±1.07
16.8±3.9 22.23±1.42 30.68±5.22
HLA-G
1±0 1.06±0.06 1±0
CYTOKINES RECEPTOR 1±0 1±0 1.22±0.16
CXCR3
1.37±0.1 1.18±0.06 1.38±0.1 OTHER MOLECULES
1.3±0.06 1.37±0.1 1.24±0.05
CD 107a
1.16±0.12 1.7±0.58 1.2±0.1
CCR7
1.3±0.04 1.06±0.03 1.2±0.06 1±0 1.5±0.4 1.12±0.05
1.47±0.17 1.1±0.04 1.17±0.1
NG2
26.16±12.1 3.46±0.64 7.3±1.32
CXCR5
1.23±0.05 1.1±0.06 1.3±0.12 17.45±6.1 12±9.16 12.05±6.48
1.07±0.04 1.2±0.05 1.33±0.05
JAGGED 1
1.17±0.07 1.13±0.1 1.27±0.04
CD 119
2.57±0.37 2.91±1.17 4.65±0.45 1.12±0.12 1.1±0.15 1.12±0.07
1.6±0.14 2.4±0.3 3.2±0.4
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DISCUSSION 
 
Adult stem cell-based approaches are promising tools for the treatment of different human 
inflammatory and autoimmune diseases. There are several reports regarding the 
beneficial roles of the immunomodulatory effects of different stem cell types (mainly 
MSCs) in disease models, such as graft-versus-host disease (GvHD)49, experimental 
autoimmune encephalomyelitis (EAE)50, inflammatory bowel disease (IBD)51, and systemic 
lupus erythematous (SLE)52. Moreover, the safety and efficacy of MSC treatments have 
been validated in clinical trial53-55 and many other are currently on progress.  
Fetal stem cells can be isolated from different gestational tissues, such as umbilical cord 
blood56, Wharton’s Jelly57, amniotic fluid (AF)14, amnion and chorionic layers58, and are 
excellent alternatives to adult stem cells.  
AFS cells are a subpopulation of fetal stem cells with potential therapeutic applications. 
AFS cells share some features of pluripotent stem cells, as they are capable of 
differentiating into cells belonging to all the three germ layers under specific conditions14 
and can form embryoid bodies, which are the main step in the differentiation of pluripotent 
embryonic stem cells 59. 
On the basis of the available data, AFS cells may have a number of advantages in 
comparison to other stem cells types, including adult stem cells, embryonic stem cells or 
iPSCs. In fact, while adult stem cells can be difficult to isolate from their niches and 
embryonic stem cells require embryo disaggregation, AFS cells can be easily obtained 
without ethical concerns from the amniotic fluid during delivery or diagnostic 
amniocentesis. Actually, the safety of amniocentesis has been established by several 
studies documenting an extremely low overall fetal loss rate (0.06-0.83%) related to this 
procedure60, and AFS cells can be obtained from samples without interfering with 
diagnostic procedures61. In addition, AFS cells have a stable genome and do not form 
tumors where injected in vivo 61-63, while embryonic stem cells and iPSCs are tumorigenic, 
adult stem cells can harbor genetic alterations occurring with aging, and iPSCs may 
accumulate genetic alterations during expansion in culture. Finally, adult somatic cell 
reprogramming is a complex process that requires the introduction of exogenous factors. 
By contrast, first trimester AFS cells can be reprogrammed with high efficiency and stable 
pluripotent phenotype only by using a chemical substance, thus reducing the risks 
associated with the random integration of the reprogramming transgenes into the host 
genomes64-66. 
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The effectiveness of AFS cells after transplantation reside in their abilities to reach and 
engraft into damage tissues and differentiate or induce resident cells into functionally-
competent types, and their beneficial effects have been validated in various disease 
models. For instance, AFS cells integrate into skeletal muscle of HSA-Cre,SMNF7/F7 
mutant mice, improving the muscle functionality through the restoration of muscle cell 
niche67. Another work described the engraftment of AFS cells into nude mice with lung 
damage, and their expression of specific alveolar or bronchiolar epithelial markers in 
response to the type of lung damage19. Finally, recent works elucidated the regenerative 
potential of AFS cells into bone, kidney and neural cells, highlighting the plasticity of AFS 
cells to respond in different ways to various types of injury models68,69. 
Our study carried out for the first time the immunological comparison of AFS cells derived 
from different gestational age; so far, only comparative studies between 1st and 2nd 
trimester-AFS cells dealing with gene expression pattern were available. It has been 
demonstrated that cKit+ 1st trimester-AFS cells belong to the most undifferentiated portion 
of amniotic fluid cell population. Such AFS cell subset displayed a cell-specific expression 
of pluripotency molecules, such as NANOG, SSEA3, TRA-1-60 and TRA-1-81, and a 
higher expression of organ-specific genes, as compared to 2nd trimester-AFS cells31. 
These findings are in agreement with the higher expression by 1st trimester AFS cells, as 
compared to other AFS cells, of NG2 and CD34 that are two molecules typical of 
undifferentiated stem cell subsets. In several adult tissues, CD34+ cells represent a distinct 
cell population with enhanced self-renewal, higher colony forming unit efficiency and long-­‐
term proliferative capacity, and is also found in embryonic stem cell-derived MSCs 70. 
The immunomodulatory effect of AFS cells observed in our experiments could explain 
some aspects of their efficacy and differentiation potential in vivo. Under inflammatory 
conditions, stimulation of AFS cells with IFN-γ and TNF-α induced an immunophenotypical 
switch, which was consistent with the immunomodulatory properties observed. As 
previously described in MSCs 47, the priming-dependent decrease of sensitivity to NK cell 
lysis of AFS cells could be explained by the overexpression of HLA-ABC and the weak 
expression of ULBPs and MICA/B which are, respectively, the main inhibitory and activator 
ligands of NK cells.  
Another potential mechanism involved in the AFS cell immune properties, which we 
observed in the T cell proliferation assay, is the increased expression of PD-L1, ICAM-1 
and VCAM-1, the latter two involved in the tethering of IECs. All these immunological 
features may be correlated with the lack of rejection of AFS cells once injected in vivo, but 
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also with their engraftment capability, and could have a synergic effect in a context of 
injured tissues, in which these stem cells can divide and preserve the SC pool and their 
functionality, thus supporting tissue regeneration.   
Our observations confirmed the pivotal role of inflammatory priming for the acquisition of 
the immunomodulatory properties of AFS cells, otherwise supportive rather than inhibitory 
cells, as previously shown by our group in MSCs and stem cells of different origin27. In 
particular, in absence of pro-inflammatory cytokines, such as IFN-γ, TNF-α and IL-1β, 
stem cells have an anti-apoptotic/pro-survival effect on IECs. On the contrary, 
inflammatory cytokine addition makes stem cells switch towards the immunosuppressive 
phenotype. At resting conditions, 2nd and 3rd trimester-AFS cells enhanced the viability of 
un-stimulated IECs, thus showing that their immunosuppressive effect is not a constitutive 
behavior of AFS cells but it is acquired upon IEC activation. By contrast, 1st trimester-AFS 
cells increased the survival of B cells, but not NK cells, and when these stem cells were 
co-cultured with resting T cells a significant increase of T cell apoptosis was induced. 
These differences between 1st trimester-AFS cells and AFS cells of the other two following 
trimesters regard also immunosuppression mechanisms. The strong inhibitory effect on T 
cell proliferation of 1st trimester-AFS cells is probably related to their pro-apoptotic effect 
towards these IECs, but also to their inability to enhance T cell viability at resting 
conditions. Moreover, as compared to 2nd and 3rd trimester-AFS cells, 1st trimester-AFS 
cells possess an IDO-independent mechanism, as shown by the lack of rescue effect by 
using IDO inhibitors such as L1-MT. Further studies will be carried out in our lab to clarify 
these mechanisms. 
Overall, our experiments have provided for the first time new insights on the 
immunological features of AFS cells isolated at different gestational age. We have 
highlighted the differences in term of expression of immunological markers, combining 
these findings with their immunological behavior towards various IECs. The efficacy of 
stem cells is not only related to their differentiation capacities, but also to their capability of 
regulating the microenvironment through the release of trophic and immunomodulatory 
molecules playing a fundamental role in tissue homeostasis. The activation of immune 
response is a crucial step in the development and progression of degenerative diseases; 
thus, understanding these mechanisms may help to identify novel therapeutic approaches. 
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